Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer

Exclusion Criteria

• •1. Have previously received any co-stimulatory or co-inhibitory T cell receptor antibody or drug therapy, including PD-1, PD-L1, PD-L2, CD137, CTLA-4, etc.
• •2. Have previously received anti-HER2 targeted therapy (monoclonal antibody or small molecule TKI).
• •3. Have any active autoimmune diseases or autoimmune diseases in the past 2 years.
• •4. Have used immunosuppressive drugs within 4 weeks before the first dose of study drug treatment.
• •5. Allergic to any monoclonal antibody or chemotherapeutic drug preparation component.
• •6. Receive a live attenuated vaccine within 4 weeks before the first dose of study drug treatment.
• •7. Known symptomatic central nervous system metastases and/or cancerous meningitis. If subjects with brain metastases who have been treated in the past are in stable condition, they could be enrolled.
• •8. Pleural and abdominal effusion requiring clinical treatment, or third interspace effusion.
• •9. Suffering from congenital or acquired immune deficiency.
• •10. Known history of human immunodeficiency virus (HIV) infection.
• •11. Subjects who have received allogeneic tissue/solid organ transplantation.
• •12. Known to have active tuberculosis.
• •13. Known to have acute or chronic active hepatitis B or acute or chronic active hepatitis C.
• •14. Severe infections that are active or poorly clinical controlled.
• •15. Known history of (non-infectious) pneumonia requiring steroid treatment or currently suffering from pneumonia.
• •16. Other poorly controlled comorbidities.
• •17. Pregnancy or breastfeeding or planning to pregnancy or childbirth during the study period.
• •18. Have uncontrolled cardiac clinical symptoms or diseases.
• •19. Malignant tumors that are progressing or require active treatment in the past 5 years, except for the following: (1) Malignant tumors that have been completely relieved for at least 2 years before enrollment and no other treatment is required during the study period; (2) Non-melanoma skin cancer or malignant freckle-like nevus that has been adequately treated and has no evidence of disease recurrence; (3) Carcinoma in situ with adequate treatment and no evidence of disease recurrence.
• •20. According to the judgment of the investigator, the patient has other factors that may affect the results of the study or cause the study to be terminated halfway.